References
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. [Internet]. 2020 Feb 15 [cited 2021 Aug 24];395(10223):507–513. Available from: http://www.thelancet.com/article/S0140673620302117/fulltext
- Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. [Internet]. 2020 Apr 7 [cited 2021 Aug 24];323(13):1239–1242. Available from: https://jamanetwork.com/journals/jama/fullarticle/2762130
- Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. [Internet]. 2020 Mar 17 [cited 2021 Aug 24];323(11):1061–1069. Available from: https://jamanetwork.com/journals/jama/fullarticle/2761044
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. [Internet]. 2020 Feb 15 [cited 2021 Aug 24];395(10223):497–506. Available from: http://www.thelancet.com/article/S0140673620301835/fulltext
- Shi H, Han X, Jiang N, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis. [Internet]. 2020 Apr 1 [cited 2021 Aug 24];20(4):425–434. Available from: http://www.thelancet.com/article/S1473309920300864/fulltext
- Polak SB, Van Gool IC, Cohen D, et al. A systematic review of pathological findings in COVID-19: a pathophysiological timeline and possible mechanisms of disease progression. Mod Pathol. [Internet]. 2020 Jun 22 [cited 2021 Aug 24];33(11):2128–2138. Available from https://www.nature.com/articles/s41379-020-0603-3
- Cabrera-Benitez NE, Laffey JG, Parotto M, et al. Mechanical ventilation–associated lung fibrosis in acute respiratory distress syndrome a significant contributor to poor outcome. Anesthesiology. [Internet]. 2014 Jul 1 [cited 2021 Aug 24];121(1):189–198. Available from: http://pubs.asahq.org/anesthesiology/article-pdf/121/1/189/266079/20140700_0-00032.pdf
- Huang Y, Tan C, Wu J, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. [Internet]. 2020 Jun 29 [cited 2021 Aug 24];21(1):1–10. Available from:
- Santus P, Flor N, Saad M, et al. Trends over time of lung function and radiological abnormalities in COVID-19 pneumonia: a prospective, observational, cohort study. J Clin Med. [Internet]. 2021 Mar 2 [cited 2021 Sep 23];10(5):1021. Available from: https://www.mdpi.com/2077-0383/10/5/1021/htm
- Barisione G, Brusasco V. Lung diffusing capacity for nitric oxide and carbon monoxide following mild-to-severe COVID-19. Physiol Rep. 2021 Feb;9(4):e14748.
- Mo X, Jian W, Su Z, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J. [Internet]. 2020 May 7 [cited 2021 Aug 24];55(6):2001217. Available from: https://erj.ersjournals.com/content/early/2020/05/04/13993003.01217-2020
- Lombardi F, Calabrese A, Iovene B, et al. Residual respiratory impairment after COVID-19 pneumonia. BMC Pulm Med. [Internet]. 2021 Jul 17 [cited 2021 Aug 5];21(1):241. Available from: http://www.ncbi.nlm.nih.gov/pubmed/34273962
- Arnold DT, Hamilton FW, Milne A, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. [Internet]. 2021 Apr 1 [cited 2021 Aug 24];76(4):399–401. Available from: https://thorax.bmj.com/content/76/4/399
- Huang W, Wu Q, Chen Z, et al. The potential indicators for pulmonary fibrosis in survivors of severe COVID-19. J Infect. [Internet]. 2021 Feb 1 [cited 2021 Jul 15];82(2):e5–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32998036
- Safonta B, Tarrasoa J, Rodriguez-Borjab E, et al. Lung function, radiological findings and biomarkers of fibrogenesis in a cohort of COVID-19 patients six months after hospital discharge. Ann Oncol. 2020 January;19–21.
- Antonio GE, Wong KT, Hui DS, et al. Thin-section CT in patients with severe acute respiratory syndrome following hospital discharge: preliminary experience. Radiology. 2003 Sep;228(3):810–815.
- Das KM, Lee EY, Singh R, et al. Follow-up chest radiographic findings in patients with MERS-CoV after recovery. Indian J Radiol Imaging. 2017. DOI:https://doi.org/10.4103/ijri.IJRI_469_16.
- Zhang P, Li J, Liu H, et al. Long-term bone and lung consequences associated with hospital-acquired severe acute respiratory syndrome: a 15-year follow-up from a prospective cohort study. Bone Res. [Internet]. 2020 [cited 2021 Sep 24];8: Available from:.;. http://www.ncbi.nlm.nih.gov/pubmed/32128276
- Raghu G, Rochwerg B, Zhang Y, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis: an update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3–19.
- Flaherty KR, Wells AU, Cottin V, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. N Engl J Med. [Internet]. 2019 Oct 31 [cited 2021 Nov 10];381(18):1718–1727. Available from:
- Nile SH, Nile A, Qiu J, et al. COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. [Internet]. 2020 Jun 1 [cited 2021 Sep 11];53:66–70. Available from: /pmc/articles/PMC7204669/
- Seifirad S. Pirfenidone: a novel hypothetical treatment for COVID-19. Med Hypotheses. [Internet]. 2020 Nov1 [cited 2021 Aug 21];144:11005. Available from /pmc/articles/PMC7297676/
- Wollin L, Wex E, Pautsch A, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur Respir J. 2015;45:1434–1445.
- Vitiello A, Pelliccia C, Ferrara F. COVID-19 patients with pulmonary fibrotic tissue: clinical pharmacological rational of antifibrotic therapy. Sn Compr Clin Med. [Internet]. 2020 Oct [cited 2021 Sep 11];2(10):1–4. Available from:. /pmc/articles/PMC7452615/
- Richeldi L, Du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–2082.
- Zhang TSL. [Comparison of clinical and pathological features between severe acute respiratory syndrome and coronavirus disease 2019]. Zhonghua Jie He He Hu Xi Za Zhi = Zhonghua Jiehe He Huxi Zazhi = Chinese J Tuberc Respir Dis. 2020 Jun;43(6):496–502.
- Potere N, Valeriani E, Candeloro M, et al. Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Crit Care. [Internet]. 2020 Jul 2 [cited 2021 Sep 11];24(1):1–12. Available from:
- No Title. COVID-19 Treatment Guidelines Panel. Coronavirus disease 2019 (COVID-19) treatment guidelines. National Institutes of Health. Available from: https://www.covid19treatmentguidelines.nih.gov/
- Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. [Internet]. 2020 Jun 9 [cited 2021 Nov 10];323(22):2329. Available from: https://jamanetwork.com/journals/jama/fullarticle/2765302
- Umemura Y, Mitsuyama Y, Minami K, et al. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: an interventional study. Int J Infect Dis. 2021 Jul 1;108:454–460.
- Pan LH, Yamauchi K, Uzuki M, et al. Type II alveolar epithelial cells and interstitial fibroblasts express connective tissue growth factor in IPF. Eur Respir J. 2001;17(6):1220–1227.
- Lipson KE, Wong C, Teng Y, et al. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair. 2012;5(Suppl 1):S24.
- Wang Q, Usinger W, Nichols B, et al. Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease. Fibrogenesis Tissue Repair. [Internet]. 2011 Feb 1 [cited 2021 Sep 11]; 4(1): Available from: /pmc/articles/PMC3042008/
- Raghu G, Anstrom KJ, King TE, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366(21):1968–1977.
- Martinez FJ, De Andrade JA, Anstrom KJ, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2093–2101.
- Oldham JM, Ma SF, Martinez FJ, et al. TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2015;192(12):1475–1482.
- Shi Z, Puyo CA. N-Acetylcysteine to combat COVID-19: an evidence review. Ther Clin Risk Manag [Internet]. 2020 [cited 2021 Sep 11];16:1047–1055. Available from: /pmc/articles/PMC7649937/
- Ibrahim H, Perl A, Smith D, et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clin Immunol. 2020 Oct;219:108566.
- Taher A, Lashgari M, Sedighi L, et al. A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome. Pharmacol Rep [Internet]. 2021 [cited 2021 Sep 11];1: Available from: /pmc/articles/PMC8191712/
- de Alencar JCG, Moreira CL, Müller AD, et al. Double-blind, randomized, placebo-controlled trial with n-acetylcysteine for treatment of severe acute respiratory syndrome caused by coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2021 Jun 1;72(11):e736–41.
- Averyanov A, Koroleva I, Konoplyannikov M, et al. First-in-human high-cumulative-dose stem cell therapy in idiopathic pulmonary fibrosis with rapid lung function decline. Stem Cells Transì Med. 2020 Jan;9(1):6–16.
- Vishnupriya M, Naveenkumar M, Manjima K, et al. Post-COVID pulmonary fibrosis: therapeutic efficacy using with mesenchymal stem cells - How the lung heals. Eur Rev Med Pharmacol Sci. 2021 Mar;25(6):2748–2751.
- Bari E, Ferrarotti I, Saracino L, et al. Mesenchymal stromal cell secretome for post-COVID-19 pulmonary fibrosis: a new therapy to treat the long-term lung sequelae? Cells. 2021 May 14;10(5):1203.
- Skurikhin E, Nebolsin V, Widera D, et al. Antifibrotic and regenerative effects of treamid in pulmonary fibrosis. Int J Mol Sci. [Internet]. 2020 Nov8 [cited 2021 Sep 11];21(21):8380. Available from: https://www.mdpi.com/1422-0067/21/21/8380/htm
- Chen MC, Korth, CC, Harnett, MD. A Randomized Phase 1 Evaluation of Deupirfenidone, a Novel Deuterium-Containing Drug Candidate for Interstitial Lung Disease and Other Inflammatory and Fibrotic Diseases Clin Pharmacol Drug Dev. 2021. doi:https://doi.org/10.1002/cpdd.1040.
- Singh VK, Seed TM. BIO 300: a promising radiation countermeasure under advanced development for acute radiation syndrome and the delayed effects of acute radiation exposure. Expert Opin Investig Drugs. 2020 May 3;29(5):429–441.
- Jackson IL, Zodda A, Gurung G, et al. BIO 300, a nanosuspension of genistein, mitigates pneumonitis/fibrosis following high-dose radiation exposure in the C57L/J murine model. Br J Pharmacol. [Internet]. 2017 Dec 1 [cited 2021 Sep 23];174(24):4738–4750. Available from: https://experts.umn.edu/en/publications/bio-300-a-nanosuspension-of-genistein-mitigates-pneumonitisfibros
- Gong L, Li Y, Nedeljkovic-Kurepa A, et al. Inactivation of NF-jB by genistein is mediated via Akt signaling pathway in breast cancer cells. Oncogene. [Internet]. 2003;22:4702–4709. Available from: www.nature.com/onc
- Ippolito E, Fiore M, Greco C, et al. COVID-19 and radiation induced pneumonitis: overlapping clinical features of different diseases. Radiother Oncol. 2020 Jul 1;148:201–202.
- Venkataraman T, Frieman MB. The role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis. Antiviral Res. 2017;143:142–150. Elsevier B.V.
- Tzouvelekis A, Ntolios P, Karameris A, et al. Increased expression of epidermal growth factor receptor (EGF-R) in patients with different forms of lung fibrosis. Biomed Res Int. 2013;2013:1–11.
- Li F, Goff SP. Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J Virol. 2015 Feb;89(4):1954–1964.
- Jolly L, Stavrou A, Vanderstoken G, et al. Influenza promotes collagen deposition via αvβ6 integrin-mediated transforming growth factor β activation. J Biol Chem. 2014 Dec 19;289(51):35246–35263.
- Meliopoulos VA, Van de Velde LA, Van de Velde NC, et al. An epithelial integrin regulates the amplitude of protective lung interferon responses against multiple respiratory pathogens. PLoS Pathog. 2016 Aug 9;12(8):e1005804.
- Chen YJ, Wang SF, Weng IC, et al. Galectin-3 enhances avian H5N1 Influenza A virus–induced pulmonary inflammation by promoting NLRP3 inflammasome activation. Am J Pathol. 2018 Apr 1;188(4):1031–1042.
- MacKinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012;185(5):537–546.
- Cox N, Pilling D, Gomer RH. Serum amyloid P: a systemic regulator of the innate immune response. J Leukoc Biol. [Internet]. 2014 Nov1 [cited 2021 Sep 11];96(5):739–743. Available from:
- Horváth A, Andersen I, Junker K, et al. Serum amyloid P component inhibits influenza A virus infections: in vitro and in vivo studies. Antiviral Res. 2001 Oct 1;52(1):43–53.
- Pilling D, Gomer RH. Persistent lung inflammation and fibrosis in serum amyloid P component (APCs-/-) knockout mice. PLoS One. 2014 Apr 2;9(4):e93730.
- Zuo W, Zhao X, Che Y-G. SARS coronavirus and lung fibrosis. Mol Biol SARS-Coronavirus. 2010;247–258 doi:https://doi.org/10.1007/978-3-642-03683-5_15.
- Chen W-C, Chen N-J, Chen H-P, et al. Nintedanib reduces neutrophil chemotaxis via activating GRK2 in bleomycin-induced pulmonary fibrosis. Int J Mol Sci. []. 2020 Jul 2 [cited 2021 Nov 10];21(13). Available from: http://www.ncbi.nlm.nih.gov/pubmed/32630825
- Wollin L, Maillet I, Quesniaux V, et al. Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis. J Pharmacol Exp Ther. Internet] 2014 May [cited 2021 Nov 10];349(2):209–220. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24556663
- Zhan X, Zhao Z, Li T. Post-inflammatory pulmonary fibrosis in a discharged COVID-19 patient: effectively treated with Pirfenidone. Arch Pulmonol Respir Care. Internet]. 2020 Jun 23 [cited 2021 Nov 20];51–53. Available from: https://www.peertechz.com/articles/APRC-6-153.php
- Momen ABI, Khan F, Saber S, et al. Usefulness of pirfenidone in COVID lung: a case series. Eur J Med Heal Sci. Internet]. 2021 Jan 19 [cited 2021 Nov 20];3(1):24–26. Available from: https://ejmed.org/index.php/ejmed/article/view/670
- Ogata H, Nakagawa T, Sakoda S, et al. Nintedanib treatment for pulmonary fibrosis after coronavirus disease 2019. Respirol Case Rep. [Internet]. 2021 May [cited 2021 Nov 20];9(5):e00744. Available from: http://www.ncbi.nlm.nih.gov/pubmed/33815804
- Chakrabortty R, Rahman S, Jahan R, et al. Nintedanib in the management of pulmonary fibrosis after COVID-19: a case report. BIRDEM Med J. [[Internet]. 2021 Apr 23 [cited 2021 Nov 20];11(2):148–152. Available from: https://www.banglajol.info/index.php/BIRDEM/article/view/53139
- Sonnweber T, Sahanic S, Pizzini A, et al. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. Eur Respir J. 2021;57(4):2003481.
- Lerum TV, Aaløkken TM, Brønstad E, et al. Dyspnoea, lung function and CT findings 3 months after hospital admission for COVID-19. Eur Respir J. 2021;57(4):2003448.